Metronomic gemcitabine suppresses tumour growth, improves perfusion and reduces hypoxia in human pancreatic ductal adenocarcinoma

Decreased Blood Flow with Increased Metabolic Activity: A Novel Sign of Pancreatic Tumor Aggressiveness

(2009) G. Komar et al.   CLINICAL CANCER RESEARCH

Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer

(2009) Atsuko Soeda et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study

(2008) S. A. Veltkamp et al.   CLINICAL CANCER RESEARCH

Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer

(2008) Silvia Dellapasqua et al.   JOURNAL OF CLINICAL ONCOLOGY

Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model

(2008) B. Laquente et al.   MOLECULAR CANCER THERAPEUTICS

Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia

(2007) Agustin A. Garcia et al.   JOURNAL OF CLINICAL ONCOLOGY